Investors
XLerateHealth maintains relationships with investors, venture capitalists and angels across the nation to provide funding exposure and coaching to the startups it supports
OCA Ventures is a venture capital firm focused on equity investments in companies with dramatic growth potential, primarily in technology and highly-scalable services businesses. Over the last decade, OCA has invested three funds in over 45 companies. The spinoff OCA EDGE fund invests smaller amounts in seed or very early stage rounds of highly scalable technology businesses.
River Cities Capital Funds invests in market-validated, fast-growing healthcare and information technology companies in the less efficient, lower end of the growth equity market. With over $500 million of capital raised and a consistent track record of entrepreneurial success, River Cities has established itself as a preferred source of growth capital. The firm is actively seeking new investments for its fifth fund.
Chrysalis Ventures manages one of Mid-America’s largest funds for early-stage and growth investments, primarily in the Healthcare and Technology sectors. Headquartered in Louisville, Kentucky, Chrysalis has approximately $400 million under management and has invested in over 65 companies since 1993.
ID Ventures provides investment capital and resources to early-stage, high-growth companies throughout Michigan. ID Ventures manages three industry agnostic investment funds with over $20M in assets under management and has invested in over 140 Michigan-based start-ups. Deploying several million in capital per year, IDV was ranked by Pitchbook in 2019 as the 2nd most active VC in the Great Lakes Region and the most active VC in Michigan.
Render Capital is a $15 million regional fund of Access Ventures, an impact investment firm in Louisville, KY. Render Capital invests in businesses of all kinds in the Louisville and Southern Indiana area. We seek to invest using creative capital forms that best fit the company’s particular business model and stage of development.
BioStar Capital focuses on making transformational investments in medical technologies that impact patients’ lives. With a primary emphasis on the cardiovascular and orthopedic sectors, the firm also invests in digital health, robotics, ophthalmology, neuromodulation, and biomaterials. The BioStar team represents a unique collaboration between experienced investment professionals and practicing clinicians with global reputations.
The Michigan Biomedical Venture Fund invests in biomedical startups in the domain of therapeutics, devices, diagnostics, or health IT. The fund is a collaborative effort between the University of Michigan’s (U-M) College of Engineering’s Center for Entrepreneurship and U-M Medical School’s Fast Forward Medical Innovation program. This fund is exclusively for biomedical startups or companies with U-M IP or license. With a $3 million gift from the Monroe-Brown Foundation, the MBVF awards range from $50,000-300,000.
